Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
The Journal of Invasive Cardiology|January 17, 2020
ST-Segment Elevation Myocardial Infarction and Out-of-Hospital Cardiac Arrest: Contemporary Management From the Multicenter START RegistryMeena Zareh, Jeffrey J Rade, Joseph L Thomas, et al.Blood Cancer Discovery|January 18, 2021
A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemiaLuca Tottone, Olga Lancho, Jui-Wan Loh, et al.Blood|January 3, 2024
Single-cell landscape of idiopathic multicentric Castleman disease in identical twinsJason Yongsheng Chan, Jui Wan Loh, Jing Quan Lim, et al.Science Translational Medicine|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myelomaAdam S Sperling, Benjamin A Derman, Sarah Nikiforow, et al.Microorganisms|September 28, 2024
SARS-CoV-2 Genotyping Highlights the Challenges in Spike Protein Drift Independent of Other Essential ProteinsJeremy W Prokop, Sheryl Alberta, Martin Witteveen-Lane, et al.Physiological Genomics|March 12, 2025
From castaways to discoveries: unveiling treasures in skin RNAseq using a novel multidimensional data processing workflow including infection-host dynamicsDisha Bhargava, Alec Labadie, Rebecca L Hanson-Rios-Stutz, et al.Critical Care Explorations|June 14, 2021
Dysnatremia and 6-Month Functional Outcomes in Critically Ill Patients With Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort StudyJeremy Cohen, Anthony Delaney, James Anstey, et al.Cell Reports. Medicine|March 4, 2022
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosisJosephine Hendrikson, Ying Liu, Wai Har Ng, et al.Journal of Medicinal Chemistry|November 22, 2024
Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular AdministrationJean-Baptiste Langlois, Silke Brenneisen, Stephane Rodde, et al.Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.Pageof 14